An expanding portfolio of next generation sequencing (NGS) panels and library preparation products for the accurate detection of genetic variants.
A broad range of array products for cytogenetics, rare disease, cancer and reproductive health research.
12 June 2018
OGT expands custom NGS cancer panel content
Increased NGS content provides even more flexibility for customisation
9 April 2018
OGT announces organisational changes
On 1st April 2018 Dr John Anson took over as CEO from Dr Mike Evans, who has become a non-executive director of OGT’s board.